+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Investigation Report on Chinese Rituximab Market - 2018-2022

  • ID: 4600334
  • Report
  • July 2018
  • Region: China
  • 30 Pages
  • China Research & Intelligence


  • Genentech
  • Roche
Rituximab (Roche's trade name: Rituxan) is a human-mouse chimeric anti-CD20 monoclonal antibody that was approved for the treatment of tumors in 1997. With the deep understanding of B cells and their mechanisms of action, the therapeutic range of Rituximab has expanded from B-cell malignancies to autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus, idiopathic thrombocytopenic purpura, etc.

The global sales of Rituximab have been very mature. In fiscal year 2017, Rituximab recorded a revenue of CHF 7.388 billion, a YOY increase of 1.21%. The drug was mostly used for tumor treatment. In fiscal year 2017, the sales value from tumor treatment reached CHF 5.832 billion, increasing by 0.15% YOY, and the sales value from the treatment of autoimmune diseases reached CHF 1.556 billion, increasing by 5.35% YOY. In China, Roche's Rituximab is mainly used to treat non-Hodgkin lymphoma.

As a major malignant lymphoma, non-Hodgkin lymphoma takes up a much larger proportion of malignant lymphoma than Hodgkin's disease in China. The incidence of non-Hodgkin's lymphoma has risen rapidly from 20 cases per 1 million people at the end of the 20th century to 70 cases per 1 million people today. Autoimmune diseases may affect organs such as the central nervous system, lungs, liver and kidneys, cause dysfunction or even failure of organs, and ultimately threaten life. Statistics show that there are about 30 to 40 million people suffering from autoimmune diseases in China, which leads to a growing demand for Rituximab. In 2017, the sales value of Rituximab exceeded CNY 1 billion in China.

by July 2018, there has been no China-made Rituximab on the market, and the market is monopolized by the products of Roche and its subsidiary Genentech. Several domestic manufacturers have applied for approval to produce generic Rituximab. It is expected that generic Rituximab will be launched after 2020. There is still a large growth potential for the Chinese Rituximab market.

Topics Covered:

  • Development environment of Chinese Rituximab market
  • Sales of Rituximab in China
  • Prices of Rituximab in China
  • Progress of generic Rituximab in China
  • Prospects of Chinese Rituximab Market, 2018-2022
Note: Product cover images may vary from those shown


  • Genentech
  • Roche

1 Basic Concepts of Rituximab
1.1 Indications for Rituximab
1.2 Development History of Rituximab in China
1.3 Governmental Approval of Rituximab in China

2 Sales of Rituximab in China, 2013-2017
2.1 Sales Value of Rituximab
2.1.1 Overall Sales Value
2.1.2 Sales Value in Parts of China
2.2 Sales Volume of Rituximab
2.2.1 Overall Sales Volume
2.2.2 Sales Volume in Parts of China
2.3 Sales of Rituximab by Dosage Form

3 Major Rituximab Manufacturers in China, 2013-2017
3.1 Market Share of Major Rituximab Manufacturers in China
3.1.1 Market Share by Sales Value
3.1.2 Market Share by Sales Volume
3.2 Roche
3.2.1 Enterprise Profile
3.2.2 Sales of Roche's Rituximab in China
3.3 Genentech
3.3.1 Enterprise Profile
3.3.2 Sales of Genentech's Rituximab in China

4 Prices of Rituximab in China, 2017-2018
4.1 Average Prices of Rituximab in China
4.1.1 National Average Price
4.1.2 Average Price by Region
4.2 Prices of Major Manufacturers' Rituximab in China
4.2.1 Price of Roche's Rituximab in China
4.2.2 Price of Genentech's Rituximab in China

5 Prospects of Chinese Valsartan Market, 2018-2022
5.1 Factors Influencing Rituximab Development in China
5.1.1 Driving Forces and Market Opportunities
5.1.2 Threats and Challenges
5.2 Forecast on Market Size
5.3 Forecast on Competition Pattern

Selected Charts
Chart Rituximab Products Approved to Market in China by 2018
Chart Sales Value of Rituximab in China, 2013-2017
Chart Sales Value of Rituximab by Region in China, 2013-2017
Chart Market Share of Rituximab Manufacturers by Sales Value in China, 2013-2017
Chart Prices of Roche's Rituximab in Key Regions of China, 2017-2018
Chart Prices of Genentech's Rituximab in Key Regions of China, 2017-2018
Chart Forecast on Sales of Rituximab in China, 2018-2022
Chart Generic Rituximab in China

Note: Product cover images may vary from those shown


  • Roche
  • Genentech
Note: Product cover images may vary from those shown

Background research defines the range of products and industries, which proposes the key points of the research. Proper classification will help clients understand the industry and products in the report.

Secondhand material research is a necessary way to push the project into fast progress. The analyst always chooses the data source carefully. Most secondhand data they quote is sourced from an authority in a specific industry or public data source from governments, industrial associations, etc. For some new or niche fields, they also "double-check" data sources and logics before they show them to clients.

Primary research is the key to solve questions, which largely influence the research outputs. The analyst may use methods like mathematics, logical reasoning, scenario thinking, to confirm key data and make the data credible.

The data model is an important analysis method. Calculating through data models with different factors weights can guarantee the outputs objective.

The analyst optimizes the following methods and steps in executing research projects and also forms many special information gathering and processing methods.

1. Analyze the life cycle of the industry to understand the development phase and space.
2. Grasp the key indexes evaluating the market to position clients in the market and formulate development plans
3. Economic, political, social and cultural factors
4. Competitors like a mirror that reflects the overall market and also market differences.
5. Inside and outside the industry, upstream and downstream of the industry chain, show inner competitions
6. Proper estimation of the future is good guidance for strategic planning.